109 related articles for article (PubMed ID: 16897747)
1. Comprehensive assessment of DNA copy number alterations in human prostate cancers using Affymetrix 100K SNP mapping array.
Liu W; Chang B; Sauvageot J; Dimitrov L; Gielzak M; Li T; Yan G; Sun J; Sun J; Adams TS; Turner AR; Kim JW; Meyers DA; Zheng SL; Isaacs WB; Xu J
Genes Chromosomes Cancer; 2006 Nov; 45(11):1018-32. PubMed ID: 16897747
[TBL] [Abstract][Full Text] [Related]
2. Multiple genomic alterations on 21q22 predict various TMPRSS2/ERG fusion transcripts in human prostate cancers.
Liu W; Ewing CM; Chang BL; Li T; Sun J; Turner AR; Dimitrov L; Zhu Y; Sun J; Kim JW; Zheng SL; Isaacs WB; Xu J
Genes Chromosomes Cancer; 2007 Nov; 46(11):972-80. PubMed ID: 17654723
[TBL] [Abstract][Full Text] [Related]
3. TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.
Cerveira N; Ribeiro FR; Peixoto A; Costa V; Henrique R; Jerónimo C; Teixeira MR
Neoplasia; 2006 Oct; 8(10):826-32. PubMed ID: 17032499
[TBL] [Abstract][Full Text] [Related]
4. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer.
Bergamaschi A; Kim YH; Wang P; Sørlie T; Hernandez-Boussard T; Lonning PE; Tibshirani R; Børresen-Dale AL; Pollack JR
Genes Chromosomes Cancer; 2006 Nov; 45(11):1033-40. PubMed ID: 16897746
[TBL] [Abstract][Full Text] [Related]
5. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
[TBL] [Abstract][Full Text] [Related]
6. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer.
Hermans KG; van Marion R; van Dekken H; Jenster G; van Weerden WM; Trapman J
Cancer Res; 2006 Nov; 66(22):10658-63. PubMed ID: 17108102
[TBL] [Abstract][Full Text] [Related]
7. High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression.
Wolf M; Mousses S; Hautaniemi S; Karhu R; Huusko P; Allinen M; Elkahloun A; Monni O; Chen Y; Kallioniemi A; Kallioniemi OP
Neoplasia; 2004; 6(3):240-7. PubMed ID: 15153336
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer.
Laxman B; Tomlins SA; Mehra R; Morris DS; Wang L; Helgeson BE; Shah RB; Rubin MA; Wei JT; Chinnaiyan AM
Neoplasia; 2006 Oct; 8(10):885-8. PubMed ID: 17059688
[TBL] [Abstract][Full Text] [Related]
9. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
10. High-resolution genomic and expression analyses of copy number alterations in breast tumors.
Haverty PM; Fridlyand J; Li L; Getz G; Beroukhim R; Lohr S; Wu TD; Cavet G; Zhang Z; Chant J
Genes Chromosomes Cancer; 2008 Jun; 47(6):530-42. PubMed ID: 18335499
[TBL] [Abstract][Full Text] [Related]
11. High-resolution copy number and gene expression microarray analyses of head and neck squamous cell carcinoma cell lines of tongue and larynx.
Järvinen AK; Autio R; Kilpinen S; Saarela M; Leivo I; Grénman R; Mäkitie AA; Monni O
Genes Chromosomes Cancer; 2008 Jun; 47(6):500-9. PubMed ID: 18314910
[TBL] [Abstract][Full Text] [Related]
12. Minimum altered regions in early prostate cancer progression identified by high resolution whole genome tiling path BAC array comparative hybridization.
Watson SK; Woolcock BW; Fee JN; Bainbridge TC; Webber D; Kinahan TJ; Lam WL; Vielkind JR
Prostate; 2009 Jun; 69(9):961-75. PubMed ID: 19267368
[TBL] [Abstract][Full Text] [Related]
13. Morphological features of TMPRSS2-ERG gene fusion prostate cancer.
Mosquera JM; Perner S; Demichelis F; Kim R; Hofer MD; Mertz KD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; Rubin MA
J Pathol; 2007 May; 212(1):91-101. PubMed ID: 17385188
[TBL] [Abstract][Full Text] [Related]
14. Significance of the TMPRSS2:ERG gene fusion in prostate cancer.
Hossain D; Bostwick DG
BJU Int; 2013 May; 111(5):834-5. PubMed ID: 23578235
[No Abstract] [Full Text] [Related]
15. Targets of genome copy number reduction in primary breast cancers identified by integrative genomics.
Chen W; Salto-Tellez M; Palanisamy N; Ganesan K; Hou Q; Tan LK; Sii LH; Ito K; Tan B; Wu J; Tay A; Tan KC; Ang E; Tan BK; Tan PH; Ito Y; Tan P
Genes Chromosomes Cancer; 2007 Mar; 46(3):288-301. PubMed ID: 17171680
[TBL] [Abstract][Full Text] [Related]
16. Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high-resolution array-based comparative genomic hybridization.
Hosoya N; Sanada M; Nannya Y; Nakazaki K; Wang L; Hangaishi A; Kurokawa M; Chiba S; Ogawa S
Genes Chromosomes Cancer; 2006 May; 45(5):482-94. PubMed ID: 16425296
[TBL] [Abstract][Full Text] [Related]
17. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement.
Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA
Neoplasia; 2006 Jun; 8(6):465-9. PubMed ID: 16820092
[TBL] [Abstract][Full Text] [Related]
18. Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis.
Lapointe J; Li C; Giacomini CP; Salari K; Huang S; Wang P; Ferrari M; Hernandez-Boussard T; Brooks JD; Pollack JR
Cancer Res; 2007 Sep; 67(18):8504-10. PubMed ID: 17875689
[TBL] [Abstract][Full Text] [Related]
19. Plasma genetic and genomic abnormalities predict treatment response and clinical outcome in advanced prostate cancer.
Xia S; Kohli M; Du M; Dittmar RL; Lee A; Nandy D; Yuan T; Guo Y; Wang Y; Tschannen MR; Worthey E; Jacob H; See W; Kilari D; Wang X; Hovey RL; Huang CC; Wang L
Oncotarget; 2015 Jun; 6(18):16411-21. PubMed ID: 25915538
[TBL] [Abstract][Full Text] [Related]
20. Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A; Seidel A; Burkhardt L; Bachmann F; Mader M; Grupp K; Eichenauer T; Becker A; Adam M; Graefen M; Huland H; Kurtz S; Steurer S; Tsourlakis MC; Minner S; Michl U; Schlomm T; Sauter G; Simon R; Sirma H
J Pathol; 2013 Sep; 231(1):130-41. PubMed ID: 23794398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
